Home > Insider Trading > Filing (0000904454-23-000386)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1590560	Uniqure N.v.	QURE	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1717852	P. Jeremy Springhorn	C/O Uniqure N.v. Paasheuvelweg 25A Amsterdam P7 11058BP		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2023-06-13	8,700	$0.00	28,273	No	4	A	Direct
Ordinary Shares	Disposition	2023-06-16	2,286	$18.88	25,987	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Stock Option (Right to Buy)	Acquisiton	2023-06-13	17,060	$0.00	17,060	$20.18

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
17,060		2033-06-13	No	4	A	Direct

Footnotes

Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date.
The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date.
As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.86 to $18.91. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.